Sponsored by
Excellent review of all of the oncolytic viruses being used to treat Glioblastoma. Of note is the Japan has given conditional time limited approval of one of them: teserpaturev, which is a small trial showed 92% 1 year survival for recurrent Glioblastoma which is unheard of! Can't believe Japan implements conditional approvals and the USA doesn't yet!